Introduction: The majority of Psoriatic Arthritis patients experience a good clinical response to anti-Tumor Necrosis Factor (TNF)-α therapies. However, treatment failure with anti-TNF-α can represent a relevant clinical problem. Areas covered: We review the efficacy and safety profile of biological therapies that have been reported from randomized, controlled trials in phase II and phase III available in Pubmed Database for agents targeting IL-12/23p40 antibody (ustekinumab) and IL-17 (secukinumab), inhibitor of phosphodiesterase 4, (apremilast), and of JAK/STAT pathways (tofacitinib) and CTLA4 co-stimulation (abatacept) in Psoriatic Arthritis. Expert opinion: In Psoriatic Arthritis, main emerging drugs are represented by the fully human monoclonal IL-12/23p40 antibody, ustekinumab, the agent targeting IL-17, secukinumab, and the inhibitor of phosphodiesterase 4, apremilast. Results on T cell co-stimulation inhibition by abatacept are insufficient both in psoriasis and in PsA. In vitro investigations on JAK/STAT pathways in PsA suggest that tofacitinib could represent a further valuable therapeutic option. Emerging biological treatments other than anti-TNF agents, ustekinumab, secukinumab and apremilast appear promising for Psoriatic Arthritis and recent studies have showed a good efficacy and an acceptable safety profile; however, further and long-term studies are advocated

Emerging drugs for psoriatic arthritis / Caso, Francesco; DEL PUENTE, Antonio; Peluso, Rosario; Caso, Paolo; Girolimetto, Nicolò; Del Puente, Aurora; Scarpa, Raffaele; Costa, Luisa. - In: EXPERT OPINION ON EMERGING DRUGS. - ISSN 1472-8214. - 21:1(2016), pp. 69-79. [10.1517/14728214.2016.1146679]

Emerging drugs for psoriatic arthritis

CASO, FRANCESCO;DEL PUENTE, ANTONIO;PELUSO, ROSARIO;SCARPA, RAFFAELE;COSTA, LUISA
2016

Abstract

Introduction: The majority of Psoriatic Arthritis patients experience a good clinical response to anti-Tumor Necrosis Factor (TNF)-α therapies. However, treatment failure with anti-TNF-α can represent a relevant clinical problem. Areas covered: We review the efficacy and safety profile of biological therapies that have been reported from randomized, controlled trials in phase II and phase III available in Pubmed Database for agents targeting IL-12/23p40 antibody (ustekinumab) and IL-17 (secukinumab), inhibitor of phosphodiesterase 4, (apremilast), and of JAK/STAT pathways (tofacitinib) and CTLA4 co-stimulation (abatacept) in Psoriatic Arthritis. Expert opinion: In Psoriatic Arthritis, main emerging drugs are represented by the fully human monoclonal IL-12/23p40 antibody, ustekinumab, the agent targeting IL-17, secukinumab, and the inhibitor of phosphodiesterase 4, apremilast. Results on T cell co-stimulation inhibition by abatacept are insufficient both in psoriasis and in PsA. In vitro investigations on JAK/STAT pathways in PsA suggest that tofacitinib could represent a further valuable therapeutic option. Emerging biological treatments other than anti-TNF agents, ustekinumab, secukinumab and apremilast appear promising for Psoriatic Arthritis and recent studies have showed a good efficacy and an acceptable safety profile; however, further and long-term studies are advocated
2016
Emerging drugs for psoriatic arthritis / Caso, Francesco; DEL PUENTE, Antonio; Peluso, Rosario; Caso, Paolo; Girolimetto, Nicolò; Del Puente, Aurora; Scarpa, Raffaele; Costa, Luisa. - In: EXPERT OPINION ON EMERGING DRUGS. - ISSN 1472-8214. - 21:1(2016), pp. 69-79. [10.1517/14728214.2016.1146679]
File in questo prodotto:
File Dimensione Formato  
Emerging drugs for psoriatic arthritis.pdf

non disponibili

Descrizione: Articolo
Tipologia: Versione Editoriale (PDF)
Licenza: Accesso privato/ristretto
Dimensione 550.35 kB
Formato Adobe PDF
550.35 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/648250
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 34
social impact